Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Open Life Sci ; 18(1): 20220618, 2023.
Article in English | MEDLINE | ID: mdl-37333486

ABSTRACT

Curcumin is the most abundant derivative of turmeric rhizome. Although studies have proved that curcumin could inhibit the growth of tumors, its specific molecular mechanism has not yet been fully elucidated. This study aims to systematically elaborate the mechanisms of curcumin against hepatocellular carcinoma. The anti-tumor effect of curcumin was determined by the cell viability test. Flow cytometry was applied to examine the cell cycle and the apoptosis of cancer cells, and the cancer cell migration was detected by wound healing experiments. The expressions of signal transducers and activators of transcription 3 (STAT3), vascular endothelial growth factor (VEGF), and hypoxia-inducible factor-1α (HIF-1α) in cancer cells were examined by immunostaining and analyzed by the Image J analysis system. After treatment with curcumin, the apoptosis ratio of HepG2 cells increased significantly (P < 0.05). The proliferation of cancer cells was arrested at the S-phase cell cycle, and the migration of cancer cells was inhibited by the increasing concentration of curcumin, together with the decreasing expressions of STAT3, VEGF, and HIF-1α signaling pathways. The results indicate that curcumin could effectively inhibit the growth and migration of hepatocarcinoma cells by inducing cancer cell apoptosis, blocking the cancer cell cycle in the S phase, and reducing the expression of STAT3, VEGF, and HIF-1α signaling pathways.

2.
Infect Control Hosp Epidemiol ; 41(7): 772-776, 2020 07.
Article in English | MEDLINE | ID: mdl-32362296

ABSTRACT

OBJECTIVE: To prevent and control public health emergencies, we set up a prescreening and triage workflow and analyzed the effects on coronavirus disease 2019 (COVID-19). METHODS: In accordance with the requirements of the level 1 emergency response of public health emergencies in Shaanxi Province, China, a triage process for COVID-19 was established to guide patients through a 4-level triage process during their hospital visits. The diagnosis of COVID-19 was based on positive COVID-19 nucleic acid testing according to the unified triage standards of the Guidelines for the Diagnosis and Treatment of Novel Coronavirus Pneumonia (Trial version 4),4 issued by the National Health Commission of the People's Republic of China. RESULTS: The screened rate of suspected COVID-19 was 1.63% (4 of 246) in the general fever outpatient clinic and 8.28% (13 of 157) in the COVID-19 outpatient clinic, and they showed a significant difference (P = .00). CONCLUSIONS: The triage procedure effectively screened the patients and identified the high-risk population.


Subject(s)
Coronavirus Infections/diagnosis , Coronavirus Infections/prevention & control , Infection Control/methods , Pandemics/prevention & control , Pneumonia, Viral/diagnosis , Pneumonia, Viral/prevention & control , Triage/statistics & numerical data , Betacoronavirus , COVID-19 , China , Coronavirus Infections/complications , Fever/virology , Hospitals/statistics & numerical data , Humans , Mass Screening , Pneumonia, Viral/complications , Polymerase Chain Reaction , Practice Guidelines as Topic , SARS-CoV-2 , Symptom Assessment , Triage/methods , Triage/standards , Workflow
3.
Food Funct ; 8(9): 3319-3326, 2017 Sep 20.
Article in English | MEDLINE | ID: mdl-28848967

ABSTRACT

Curcumin, a derivative from the dried rhizome of curcuma longa, has been proven to possess anti-tumor effects. However, the detailed molecular mechanisms have not been fully elucidated. In this study, we aimed to explore the anti-tumor mechanisms of curcumin in treating gastric cancer. BALB/C mice grafted with a mouse gastric adenocarcinoma cell line (MFC) were used as the experimental model. Mice received different doses of curcumin after grafting. Tumor size was measured and tumor weight was determined after tumor inoculation. TUNEL assay and flow cytometric analysis were applied to evaluate the apoptosis of the cancer cells. Serum cytokines IFN-γ, TNF-α, granzyme B and perforin were detected by ELISA assay. The anti-tumor effect was determined using cytotoxic T-lymphocyte (CTL) assays and in vivo tumor prevention tests. The expression of DEC1, HIF-1α, STAT3 and VEGF in tumor tissues was examined by immunostaining and analyzed using an Image J analysis system. Compared with controls, tumor growth (size and weight) was significantly inhibited by curcumin treatment (P < 0.05). The apoptotic index in gastric cancer cells was significantly increased in the curcumin treatment group. Splenocyte cells from mice treated with curcumin exhibited higher cytolytic effects on MFC cancer cells than those from mice treated with saline (P < 0.01). The expression of DEC1, HIF-1α, STAT3 and VEGF in tumor tissues was down-regulated after curcumin treatment. Our results indicate that curcumin inhibits the proliferation of gastric carcinoma by inducing the apoptosis of tumor cells, activating immune cells to secrete a large amount of cytokines, and down-regulating the DEC1, HIF-1α, VEGF and STAT3 signal transduction pathways.


Subject(s)
Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents/administration & dosage , Carcinoma/drug therapy , Curcuma/chemistry , Curcumin/administration & dosage , Plant Extracts/administration & dosage , Stomach Neoplasms/drug therapy , Animals , Apoptosis/drug effects , Carcinoma/genetics , Carcinoma/metabolism , Carcinoma/physiopathology , Cell Line, Tumor , Cell Proliferation/drug effects , Female , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Male , Mice , Mice, Inbred BALB C , STAT3 Transcription Factor/genetics , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Stomach Neoplasms/genetics , Stomach Neoplasms/metabolism , Stomach Neoplasms/physiopathology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
4.
Oncotarget ; 7(44): 71274-71284, 2016 11 01.
Article in English | MEDLINE | ID: mdl-27713135

ABSTRACT

Alpha-fetoprotein (AFP) is a marker of hepatocellular carcinoma (HCC) and serves as a target for immunotherapy. However, current treatments targeting AFP are not reproducible and do not provide complete protection against cancer. This issue may be solved by developing novel therapeutic vaccines with enhanced immunogenicity that could effectively target AFP-expressing tumors. In this study, we report construction of a therapeutic peptide vaccine by linking heat shock protein 70 (HSP70) functional peptide to the AFP epitope to obtain HSP70-P/AFP-P. This novel peptide was administered into BALB/c mice to observe the effects. Quantification of AFP-specific CD8 + T cells that secrete IFN-γ in these mice via ELISPOT revealed the synergistic effects of HSP70-P/AFP-P with increased numbers of AFP-specific CD8 + T cells. Similarly, ELISA analysis showed increased granzyme B and perforin released by natural killer cells. Moreover, in vitro cytotoxic T-lymphocyte assays and in vivo tumor preventive experiments clearly showed the higher antitumor effects of HSP70-P/AFP-P against AFP-expressing tumors. These results show that treatment of BALB/c mice with HSP70-P/AFP-P induced stronger T-cells responses and improved protective immunity. Our data suggest that HSP70-P/AFP-P may be used as a therapeutic approach in the treatment of AFP-expressing cancers.


Subject(s)
Cancer Vaccines/immunology , HSP70 Heat-Shock Proteins/immunology , alpha-Fetoproteins/immunology , Animals , Epitopes , Female , Immunization , Killer Cells, Natural/immunology , Male , Mice , Mice, Inbred BALB C , Recombinant Proteins/immunology , T-Lymphocytes, Cytotoxic/immunology , Vaccines, Subunit/immunology
5.
Cancer Biother Radiopharm ; 28(5): 406-14, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23484810

ABSTRACT

Hepatocellular carcinoma (HCC) is one of the most common malignant gastroenterological cancers over the world. α-fetoprotein (AFP) is an oncofetal protein produced during HCC development that could generate weaker and less reproducible antitumor protection, and it may serve as a target for immunotherapy. Therefore, it is imperative to enhance its immunogenicity and develop therapeutic vaccines to eliminate AFP-expressing tumors. In this study, by way of glutaraldehyde cross-linking, we constructed a potential therapeutic protein vaccine, glycoprotein 96 (gp96)/AFP. Our results demonstrated that AFP and gp96 synergistically exhibited significant increase in AFP-specific CD8⁺ T-cell responses and impressive cytotoxic antitumor effect against AFP-expressing tumors. Priming mice with the reconstructed vaccine, we elicited robust strong protective immunity. Our study suggests that tumor vaccine by cross-linking tumor antigen and gp96 is a promising approach to cancer therapy.


Subject(s)
Cancer Vaccines/therapeutic use , Carcinoma, Hepatocellular/therapy , Immunity, Cellular/immunology , Immunotherapy , Liver Neoplasms/therapy , Membrane Glycoproteins/metabolism , alpha-Fetoproteins/metabolism , Animals , Blotting, Western , Carcinoma, Hepatocellular/immunology , Carcinoma, Hepatocellular/metabolism , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Liver Neoplasms/immunology , Liver Neoplasms/metabolism , Membrane Glycoproteins/immunology , Mice , Mice, Inbred BALB C , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , T-Lymphocytes, Cytotoxic/immunology , Vaccination , alpha-Fetoproteins/immunology
6.
Clin Chim Acta ; 417: 73-9, 2013 Feb 18.
Article in English | MEDLINE | ID: mdl-23266770

ABSTRACT

Heat shock protein 72 (HSP72) and glycoprotein 96 (gp96) are highly expressed in cancer tissues. Recent studies indicate the possible roles of HSP72 and gp96 in the development and progression of gastrointestinal carcinomas but detailed mechanisms are still ambiguous. Human esophageal cancer, gastric cancer, colon cancer and liver cancer are common gastrointestinal malignant carcinomas in the world. The studies indicated that there existed a significant correlation between the expression of HSP72, gp96 and the development and progression of digestive carcinomas. HSP72 and gp96 expression were significantly associated with the presence of tumor infiltration, lymph node and remote metastasis. Interestingly, studies have found that HSP72 chaperoned alpha-fetoprotein (AFP), HBx in hepatocellular carcinoma, and CD44 in colonic carcinomas. The further researches demonstrated that HSP72-AFP or gp96-AFP recombined vaccine could elicit specific anti-tumor immunity. The high-level expression of HSP72 and gp96 may be not only used as diagnostic or prognostic markers for gastrointestinal carcinomas but also as better immunotherapeutic vaccines in the cancers.


Subject(s)
HSP72 Heat-Shock Proteins , Membrane Glycoproteins , Animals , Digestive System Neoplasms/genetics , Digestive System Neoplasms/metabolism , Digestive System Neoplasms/pathology , Digestive System Neoplasms/therapy , Gene Expression Regulation, Neoplastic , HSP72 Heat-Shock Proteins/metabolism , Humans , Membrane Glycoproteins/metabolism
7.
Cancer Biother Radiopharm ; 27(3): 189-97, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22372558

ABSTRACT

Hepatocellular carcinoma (HCC) is one of the most common malignancies over the world. Alpha-fetoprotein (AFP) is an oncofetal protein during HCC development that could generate weaker and less reproducible antitumor protection, and it may serve as a target for immunotherapy. Therefore, it is imperative to enhance its immunogenicity and develop therapeutic vaccines to eliminate AFP-expressing tumors. In this study, by way of glutaraldehyde cross-linking, we constructed a potential therapeutic protein complex vaccine, heat shock protein 72 (HSP72)/AFP. Our results demonstrated that AFP and HSP72 synergistically exhibited significant increases in AFP-specific CD8(+) T cell responses and impressive antitumor effects against AFP-expressing tumors. Priming mice with the reconstructed vaccine, we elicited robust strong protective immunity. Our study suggests that a tumor vaccine by cross-linking tumor antigen and HSP72 is a promising approach for cancer therapy.


Subject(s)
CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/administration & dosage , Carcinoma, Hepatocellular/immunology , HSP72 Heat-Shock Proteins/administration & dosage , Liver Neoplasms/immunology , alpha-Fetoproteins/administration & dosage , Animals , Blotting, Western , Carcinoma, Hepatocellular/therapy , Cross-Linking Reagents/pharmacology , Drug Synergism , Female , Glutaral/pharmacology , HSP72 Heat-Shock Proteins/metabolism , Immunization , Immunotherapy , Liver Neoplasms/therapy , Mice , Mice, Inbred BALB C , alpha-Fetoproteins/metabolism
8.
Lipids Health Dis ; 11: 25, 2012 Feb 14.
Article in English | MEDLINE | ID: mdl-22333072

ABSTRACT

Considerable arguments remain regarding the diverse biological activities of polyunsaturated fatty acids (PUFA). One of the most interesting but controversial dietary approaches focused on the diverse function of dihomo-dietary γ-linolenic acid (DGLA) in anti-inflammation and anti-proliferation diseases, especially for cancers. This strategy is based on the ability of DGLA to interfere in cellular lipid metabolism and eicosanoid (cyclooxygenase and lipoxygenase) biosynthesis. Subsequently, DGLA can be further converted by inflammatory cells to 15-(S)-hydroxy-8,11,13-eicosatrienoic acid and prostaglandin E1 (PGE1). This is noteworthy because these compounds possess both anti-inflammatory and anti-proliferative properties. PGE1 could also induce growth inhibition and differentiation of cancer cells. Although the mechanism of DGLA has not yet been elucidated, it is significant to anticipate the antitumor potential benefits from DGLA.


Subject(s)
8,11,14-Eicosatrienoic Acid/pharmacology , Antineoplastic Agents/pharmacology , Neoplasms/drug therapy , 8,11,14-Eicosatrienoic Acid/pharmacokinetics , 8,11,14-Eicosatrienoic Acid/therapeutic use , Animals , Anti-Inflammatory Agents/pharmacokinetics , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/therapeutic use , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Humans , Inflammation/drug therapy , Neoplasms/pathology , Oxidation-Reduction
9.
Clin Dev Immunol ; 2010: 212537, 2010.
Article in English | MEDLINE | ID: mdl-20300187

ABSTRACT

Heat shock protein 72 (HSP72) and glycoprotein 96 (gp96) are highly expressed in cancer tissues. Recent studies indicate the possible roles of HSP72 and gp96 in the development and progression of gastrointestinal carcinomas but detailed information is still ambiguous. We investigated the correlation between clinicopathology and expression of HSP72 and gp96 in human esophageal squamous cell carcinoma. The expression of HSP72 and gp96 was studied in 120 human esophageal squamous cell carcinomas with or without metastasis as well as in mucous membrane adjacent to cancers by way of immunohistochemistry. HSP72 immunoreactivities were detected in 112 of 120 primary tumors (93.3%) and in 30 of 120 mucous membranes adjacent to cancers (25.0%). Gp96 detected in esophageal squamous cell carcinoma and inmucous membrane adjacent to cancer was 85.0% and 20.0%, respectively. Both HSP72 and gp96 stained in cytoplasm. HSP72 and gp96 expression in esophageal squamous cell carcinomas with metastasis was significantly higher than those with nonmetastasis (P < .05). The results indicate that there exists a significant correlation between the expression of HSP72 and gp96 and the progression of esophageal squamous cell carcinomas. HSP72 and gp96 expression were significantly associated with the presence of tumor infiltration, lymph node, and remote metastasis.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/physiopathology , Esophageal Neoplasms/metabolism , Esophageal Neoplasms/physiopathology , Mucous Membrane/metabolism , Adult , Aged , Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/pathology , Disease Progression , Esophageal Neoplasms/pathology , Female , HSP72 Heat-Shock Proteins/metabolism , Humans , Male , Membrane Glycoproteins/metabolism , Middle Aged , Mucous Membrane/pathology , Neoplasm Metastasis , Neoplasm Staging
10.
Cell Biol Int ; 32(7): 860-4, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18387829

ABSTRACT

CD44v6 is a splice variant of CD44 (CD44v), probably promoting cancer cell adherence to vascular endothelium and base membranes and enhancing the invasion and metastasis of colonic carcinomas. Heat shock protein 72 (HSP72) as a molecular chaperone has been confirmed to be overexpressed in epithelial carcinoma cells. There may be a possible association between the expression of HSP72 and CD44v6 during the growth and progression of colonic carcinoma cells. The aim of the study was to investigate the interaction between heat shock protein 72 and CD44v6 in human colonic carcinomas. The localization of HSP72 and CD44v6 in human colonic carcinomas was determined by immunohistochemistry and confocal laser microscopy. The interaction between HSP72 and CD44v6 in colonic carcinoma cells was analyzed by immunoprecipitation and Western immunoblots. Our results revealed that colonic carcinoma synchronously co-expressed higher levels of HSP72 and CD44v6 than that in adjacent normal colonic tissues. HSP72 and CD44v6 were mainly immunolocalized in the cytoplasm, and also immunolabelled on the cell membrane. Based on immunoprecipitation and Western immunoblots, we found that HSP72 was associated with CD44v6 precursor fragments in human colonic carcinoma cells. The interaction between HSP72 and CD44v6 in human colonic carcinoma cells may contribute to study the pathogenesis and immunotherapy of colonic carcinoma.


Subject(s)
Adenocarcinoma/metabolism , Colonic Neoplasms/metabolism , HSP72 Heat-Shock Proteins/metabolism , Hyaluronan Receptors/metabolism , Adult , Aged , Female , Humans , Male , Middle Aged , Protein Isoforms/metabolism
11.
J Proteome Res ; 7(12): 5133-7, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19367718

ABSTRACT

Hepatitis B virus (HBV) infection is a major factor contributing to the development of hepatocellular carcinoma (HCC) in the world. Hepatitis B virus X protein (HBx) has been verified to play an important role in hepatocarcinogenesis. Heat shock protein 72 (HSP72) as a molecular chaperone has been confirmed to overexpress in epithelial carcinoma cells. There may be a possible association between the expression of HSP72 and HBx during the growth and progression of hepatocellular carcinoma cells. The aim of the study was to investigate the relationship between heat shock protein 72 and HBx in human hepatocellular carcinomas. The localization of HSP72 and HBx in human hepatocellular carcinomas was determined by immunohistochemistry and confocal laser microscopy. The interaction between HSP72 and HBx in liver cancer cells was analyzed by immunoprecipitation and Western blot. Our results revealed that hepatocellular carcinoma synchronously co-expressed higher level of HSP72 and HBx than that in the adjacent tissues to hepatocellular carcinoma. HSP72 and HBx were mainly immunolocalized in the cytoplasm. On the basis of immunoprecipitation and Western blot, we found that HSP72 formed complex with HBx in human hepatocellular carcinoma cells. The association between HSP72 and HBx in human hepatocellular carcinoma cells may contribute to study the pathogenesis and immunotherapy of hepatocellular carcinoma.


Subject(s)
Carcinoma, Hepatocellular/metabolism , HSP72 Heat-Shock Proteins/chemistry , Liver Neoplasms/metabolism , Proteomics/methods , Trans-Activators/metabolism , Viral Regulatory and Accessory Proteins/metabolism , Cell Line, Tumor , HSP72 Heat-Shock Proteins/metabolism , Humans , Immunohistochemistry/methods , Immunoprecipitation/methods , Microscopy, Confocal/methods , Protein Binding , Proteome
SELECTION OF CITATIONS
SEARCH DETAIL
...